- The Lancet Jul. ’20: Lung Fibrosis Findings in COVID 19…
- NIH, May 20: Potential role for COVID 19 antifibrotic therapy…
- NCBI, May ’20: Lung Fibrosis Relationship to COVID 19…
- Journal of Trans. Med. Feb. ’20: TGF-β Activation of Pulmonary Fibrosis…
- Science Direct, Jan. ’18: TGF-β Mediates Renal Fibrosis via the Smad3…
- Frontiers, Jul. ’17: TGF-β & SMAD Signaling Related to Prevention of Fibrosis…
- “Kidney Int’t, Dec. ’15: Smad3/Smad4/CDK9 Complex Promotes Renal Fibrosis…
- Frontiers, Mar. ’15: TGF-β/Smad signaling in Renal Fibrosis…
- NIH, Nov. ’06: Smad3 Related to Pulmonary Fibrosis and Emphysema…
- NIH, Apr. ’04: Smad3 as a Mediator of the Fibrotic Response…
- Arm. Jour. of Physio., Mar. 02: Smad3 Deficiency Attenuates Pulmonary fibrosis…
If you are looking for a trusted office activator, this software guarantees efficient licensing for Office 2019 products.
- Oncoimmunology: “Novel TGF-b inhibitors ready for prime time in onco-immunology”
- Immunity: “TGF-b Inhibition and Immunotherapy: Checkmate”
- Human vaccines & immunotherapeutics: “Transforming growth factor-b: A therapeutic target for cancer”
- Oncogene: “Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis”
- AACR Journals Cancer Discovery: “TGF-β1-mediated Smad3 enhances PD-1 expression on antigen-specific T cells in cancer”
- The Journal of Clinical Investigation: “Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β–dependent cancer metastasis”
- Cell Death and Disease: “KLF17 empowers TGF-β/Smad signaling by targeting Smad3-dependent pathway to suppress tumor growth and metastasis during cancer progression”
- ASM Journals; Molecular and cellular biology: “Targeted Disruption of Smad3 Reveals an Essential Role in Transforming Growth Factor b-Mediated Signal Transduction”
- FEBSPress Molecular Oncology: “SMAD3/SP1 complex-mediated constitutive active loop between lncRNA PCAT7 and TGF-b signaling promotes prostate cancer bone metastasis”
- AACR Publications: “Enhanced Cancer Immunotherapy with Smad3-Silenced NK-92 Cells”
- AACR Publications: “SMAD2, SMAD3 and SMAD4 Mutations in Colorectal Cancer”